Physician profile
Alejandro B Bernal
NPI 1346253630
$3,371.46
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,881 · 2020: $706 · 2021: $516 · 2022: $268.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $761.21 | 2019-2022 | |
| Novo Nordisk INC | $381.31 | 2019-2022 | |
| Amgen INC. | $374.81 | 2019-2021 | |
| Lilly USA, LLC | $245.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $218.92 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $184.10 | 2019-2021 | |
| Pfizer INC. | $180.68 | 2019-2022 | |
| Esperion Therapeutics, INC. | $118.41 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.32 | 2019-2020 | |
| Horizon Therapeutics Plc | $109.47 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.83 | 2019-2020 | |
| Glaxosmithkline, LLC. | $82.64 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.16 | 2022 | |
| Merck Sharp & Dohme LLC | $64.23 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.33 | 2019 | |
| Amarin Pharma, INC. | $59.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $42.06 | 2019 | |
| Abbvie INC. | $31.37 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $25.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.45 | 2019 | |
| Philips North America LLC | $19.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.25 | 2021 | |
| Astellas Pharma US INC | $14.44 | 2019 | |
| Radius Health, INC. | $12.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Bernal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.